Alogliptin is a novel, highly selective and potent inhibitor of serine protease dipeptidylpeptidase-4 (DPP-4) with IC50 value of less than 10 nM [1].

Alogliptin has been reported to significantly reduce plasma DPP-4 activity and increase active GLP-1 levels in a dose-dependent manner in ob/ob?mice. Besides, alogliptin after 4?weeks administration remarkably reduced non-fasting glycosylated hemoglobin, non-fasting plasma glucose and triglyceride levels, as well as siginificantly increased non-fasting plasma insulin and fasting pancreatic insulin content in ob/ob?mice. Moreover, alogliptin treated ob/ob?mice have shown the increase of early-phase insulin secretion and the decrease of plasma glucose AUC [2]

References:
[1] Feng J,?Zhang Z,?Wallace MB,?Stafford JA,?Kaldor SW,?Kassel DB,?Navre M,?Shi L,?Skene RJ,?Asakawa T,?Takeuchi K,?Xu R,?Webb DR,?Gwaltney SL 2nd. Discovery?of?alogliptin: a?potent,?selective,?bioavailable, and?efficacious?inhibitor?of?dipeptidyl?peptidase?IV. J Med Chem.?2007 May 17;50(10):2297-300.
[2] Moritoh Y1,?Takeuchi K,?Asakawa T,?Kataoka O,?Odaka H. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice. Eur J Pharmacol.?2008 Jul 7;588(2-3):325-32.